Research - Second phase III trial confirms drug profile of plecanatide, allaying any fears that the low diarrhea rate in the first phase III was a fluke. With … Continue Reading
PremiumInsights - Gilead Sciences (GILD) reported a blowout quarter on Tuesday afternoon, topping consensus estimates across the board and possibly stopping the bleeding — at least temporarily — … Continue Reading
Read nowResearch - Regeneron’s (REGN) Praluent has been approved by the FDA, and the label essentially meets the Base Case scenario that we wrote about yesterday for Esperion … Continue Reading
PremiumResearch - Tomorrow is a big day for developmental cholesterol-lowering medications. The FDA will issue an approval decision for Regeneron (REGN) and Sanofi’s (SNY) PCSK9 inhibitor, Praluent (alirocumab).
Read nowResearch - As we theorized early this month, Tekmira Pharmaceuticals (TKMR) is changing its name and re prioritizing drug development efforts around Hepatitis B. Unfortunately, our musings that investors may reward the … Continue Reading
Read nowInsights - Healthcare investors can sleep easy tonight with one of 2015’s major unanswered questions now off the table. Celgene (CELG) will buy Receptos (RCPT) for $7.2 billion, or $232 in … Continue Reading
Read nowResearch - Cempra (CEMP) announced on Tuesday that enrollment in the phase III SOLITAIRE-IV trial is complete, and the company expects data from the study in the … Continue Reading
Read now
